Education
Anthos Therapeutics is committed to advancing the science of Factor XI inhibition through educational activities with many of the leading organizations in the field.
The information provided on this page is for educational purposes only. It is not intended to be, and should not be, understood to provide medical advice.
Patient Advocacy
Healthcare Professionals
These sites are provided as educational resources for healthcare professionals and may include products or uses that have not been approved by the US Food and Drug Administration or other regulatory agencies. Factor XI / XIa inhibitors are investigational agents and are not approved for any indication in any country.
2024
Panelists:
Christian T. Ruff, MD, MPH
Associate Professor of Medicine, Harvard Medical School; Director of General Cardiology, Brigham and Women’s Hospital; Senior Investigator, TIMI Study Group, Boston, Massachusetts
C. Michael Gibson, MS, MD
Professor of Medicine, Harvard Medical School; Interventional Cardiologist, Beth Israel Deaconess Medical Center; CEO, Nonprofit Baim Institute for Clinical Research, Boston, Massachusetts
Dr. Siddharth Patel and Dr. C Michael Gibson Discuss: Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71
Siddharth Patel, MD
Investigator at TIMI Study Group
Cardiologist at Brigham and Women’s Hospital
Disclaimer: All video and audio content is copyrighted and remains the property of clinicaltrialresults.org. Video and audio content permission has been provided by Dr. C. Michael Gibson. Authors of slides retain copyright of their slides.
Accreditation:
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.
2023
Dr. Christian T Ruff and Dr. C. Michael Gibson Discuss: Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial
Christian T. Ruff, MD, MPH
Director, General Cardiology, Brigham and Women’s Hospital; Senior Investigator, TIMI Study Group; Associate Member, Broad Institute of MIT and Harvard; Associate Professor of Medicine, Harvard Medical School
Disclaimer: All video and audio content is copyrighted and remains the property of clinicaltrialresults.org. Video and audio content permission has been provided by Dr. C. Michael Gibson. Authors of slides retain copyright of their slides.
Credit: 0.5 AMA PRA Category 1 Credit™, 0.5 ANCC contact hours, 0.5 ACPE contact hours, and ABIM MOC contact hours
Moderator:
Marc S. Sabatine, MD, MPH
Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), and a Professor of Medicine at Harvard Medical School (HMS).
Panelists:
Christian T. Ruff, MD, MPH
Director, General Cardiology, Brigham and Women’s Hospital; Senior Investigator, TIMI Study Group; Associate Member, Broad Institute of MIT and Harvard; Associate Professor of Medicine, Harvard Medical School
Jeffrey I. Weitz, MD, FRCPC, FRSC, FACP, FCCP
Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Executive Director, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Evaluating Evolving Approaches to Treating Thrombosis in Cancer: From Concept to Clinic
Faculty:
Jean M. Connors, MD
Medical Director, Hemostatic Antithrombotic Stewardship
Medical Director, Anticoagulation Management Services (Hematology Division), Brigham and Women’s Hospital/Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, United States
Alok A. Khorana, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Sondra and Stephen Hardis Chair in Oncology Research; Vice Chair, Clinical Services; Director, GI Malignancies Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
Jeffrey I. Weitz, MD, FRCPC, FRSC, FACP, FCCP
Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Executive Director, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
The information provided on this page is for educational purposes only. It is not intended to be, and should not be, understood to provide medical advice. Factor XI inhibitors, including abelacimab, are investigational agents and are not approved for any indication in any country.